Relation of Peripheral Collagen Markers to Death and Hospitalization in Patients With Heart Failure and Preserved Ejection Fraction: Results of the I-PRESERVE Collagen Substudy

Background— Heart failure with preserved ejection fraction (HFPEF) is a common and increasing public health problem. Myocardial fibrosis is a key pathological feature of HFPEF. Peripheral collagen markers may reflect this excess fibrosis; however, the relation of these markers to prognosis in patients with HFPEF has not as yet been determined. Methods and Results— This substudy of the Irbesartan in Heart Failure With Preserved Systolic Function (I-PRESERVE) trial measured plasma levels of procollagen type I amino-terminal peptide, procollagen type III amino-terminal peptide, and osteopontin in 334 patients with HFPEF. Measurements were performed at baseline and 6 months after randomization to placebo or irbesartan 300 mg/day. The relation of baseline collagen markers to the I-PRESERVE primary end point (all-cause death and hospitalization for prespecified cardiovascular causes) was evaluated by single and multivariable analysis. Similar evaluations were performed for all-cause death alone as well as heart failure events (death or hospitalization because of heart failure). Increased plasma levels of collagen markers at baseline were associated with increased frequency of the study primary end point for all collagen markers. For each 10-&mgr;g/L increase in procollagen type I amino-terminal peptide, the hazard ratio (HR) for the primary end point was 1.09 (95% CI, 1.052 to 1.13; P<0.0001); for each 10-&mgr;g/L increase in procollagen type III amino-terminal peptide procollagen type I amino-terminal peptide, the HR was 2.47 (95% CI, 0.97 to 6.33; P=0.059); and for each 10-nmol/L increase in osteopontin, the HR was 1.084 (95% CI, 1.026 to 1.15; P=0.004). No variable remained significant as an independent predictor when introduced into a multivariable model. Both treatment groups tended to reduce collagen markers, with the reduction significantly greater for placebo versus irbesartan for procollagen type III amino-terminal peptide only (P=0.0185). Conclusions— Increased peripheral collagen turnover markers were not independently associated with increased mortality and cardiovascular hospitalization in an HFPEF population on multivariable analysis but were associated on single-variable analysis. These findings provide some support to the hypothesis that pathological fibrosis in the heart, and possibly the peripheral vasculature, may be contributory to adverse clinical outcomes in patients with HFPEF. Clinical Trial Registration— URL: http://www.clinicaltrials.gov. Unique identifier: NCT00095238.

[1]  H. Krum,et al.  Abstract 315: Directly Targeting Myocardial Fibrosis with FT-011 Improves Cardiac Remodeling in Experimental Diabetic Cardiomyopathy , 2008 .

[2]  J. Emparanza,et al.  Serum carboxy-terminal propeptide of procollagen type I is a marker of myocardial fibrosis in hypertensive heart disease. , 2000, Circulation.

[3]  C. Jellis,et al.  Assessment of nonischemic myocardial fibrosis. , 2010, Journal of the American College of Cardiology.

[4]  P. Marino,et al.  Amino-terminal propeptide of type III procollagen is associated with restrictive mitral filling pattern in patients with dilated cardiomyopathy: a possible link between diastolic dysfunction and prognosis , 2004, Heart.

[5]  Daniel Levy,et al.  Relation of Disease Pathogenesis and Risk Factors to Heart Failure With Preserved or Reduced Ejection Fraction: Insights From the Framingham Heart Study of the National Heart, Lung, and Blood Institute , 2009, Circulation.

[6]  N. Afdhal,et al.  Hepatic fibrosis: Are any of the serum markers useful? , 2001, Current gastroenterology reports.

[7]  Arantxa González,et al.  Increased Collagen Type I Synthesis in Patients With Heart Failure of Hypertensive Origin: Relation to Myocardial Fibrosis , 2004, Circulation.

[8]  D. Phelan,et al.  Natural history of markers of collagen turnover in patients with early diastolic dysfunction and impact of eplerenone. , 2009, Journal of the American College of Cardiology.

[9]  Arantxa González,et al.  Biochemical assessment of myocardial fibrosis in hypertensive heart disease. , 2001, Hypertension.

[10]  M. Schellings,et al.  Matricellular proteins in the heart: possible role during stress and remodeling. , 2004, Cardiovascular research.

[11]  K. Weber,et al.  Collagen metabolism in cultured adult rat cardiac fibroblasts: response to angiotensin II and aldosterone. , 1994, Journal of molecular and cellular cardiology.

[12]  R. McKelvie,et al.  The irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial: rationale and design. , 2005, Journal of cardiac failure.

[13]  M. Volpe,et al.  Plasma osteopontin reveals left ventricular reverse remodelling following cardiac resynchronization therapy in heart failure. , 2011, International journal of cardiology.

[14]  W. Paulus,et al.  Molecular determinants of heart failure with normal left ventricular ejection fraction , 2009, Pharmacological reports : PR.

[15]  D. M. Keenan,et al.  Mechanisms of ensemble failure of the male gonadal axis in aging. , 2005, Journal of endocrinological investigation.

[16]  F. Pagani,et al.  Markers of bone turnover: biochemical and clinical perspectives. , 2005, Journal of endocrinological investigation.

[17]  Kenneth McDonald,et al.  Diastolic Heart Failure: Evidence of Increased Myocardial Collagen Turnover Linked to Diastolic Dysfunction , 2007, Circulation.

[18]  Susan Anderson,et al.  Irbesartan in patients with heart failure and preserved ejection fraction. , 2008, The New England journal of medicine.

[19]  M. Senni,et al.  Heart failure with preserved systolic function. A different natural history? , 2001, Journal of the American College of Cardiology.

[20]  F. Alla,et al.  Limitation of Excessive Extracellular Matrix Turnover May Contribute to Survival Benefit of Spironolactone Therapy in Patients With Congestive Heart Failure: Insights From the Randomized Aldactone Evaluation Study (RALES) , 2000, Circulation.